Current medical research and opinion
-
Randomized Controlled Trial Meta Analysis
Efficacy and safety of degludec insulin: a meta-analysis of randomised trials.
Degludec is a novel long-acting insulin analogue, providing an adequate supply of basal insulin over 24 hours with one daily injection, with a supposed greater reproducibility and flexibility than other basal insulins. ⋯ Degludec appears to be associated with a lower incidence of hypoglycaemia in comparison with glargine, for similar levels of glycaemic control. The use of this agent could represent one step further in insulin therapy.